NC-PERCONA
24.4.2024 15:01:28 CEST | Business Wire | Press release
Percona, a leader in enterprise-grade, open source database software, support, and services, today announced the appointment of Liz Warner as its new Chief Technology Officer, to help meet the growing demand to make data simpler, faster, and easier to manage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424498483/en/
Liz Warner, Chief Technology Officer, Percona (Photo: Business Wire)
An industry veteran, Warner comes to Percona with decades of technical and senior leadership experience; including a proven track record of driving successful organizational transformations. As CTO, she will play an instrumental role in the development and implementation of Percona’s ever-expanding collection of database solutions, including the much-anticipated Percona Everest, an open source cloud-native database platform.
“We’ve reached a pivotal moment in open source, and Percona is doubling down on its commitment to staying open through the expansion of our products and service offerings, as well as our involvement in industry-wide initiatives such as The Linux Foundation’s Valkey Community. Our accelerated growth will require a new level of strategic thinking, so I couldn’t be more excited to welcome Liz Warner to the team,” said Ann Schlemmer, CEO of Percona. “Liz brings a wealth of experience and plenty of success transforming organizations across a variety of industries. Her experience and leadership will prove invaluable to the Percona team as we continue to scale and build world-class open source database solutions.”
Most recently, Warner served as the CTO of Weaveworks, a cloud-native container management company, where she led product strategy and engineering teams. She comes to Percona with over a decade of success serving as CTO across a range of industries and organizations, including Clim8 Invest, Nationwide for Business, Motion Picture Solutions, Mettle, LendInvest, and Toyota Connected.
Warner’s appointment comes at a strategic time for Percona. After a historic 2023 — marked by sustained customer growth, multiple prestigious award wins, and several innovative product enhancements — Percona is well-positioned to bolster its position as the go-to provider of open source database solutions and support services in the months and years ahead.
The new executive appointment comes as Percona co-founder and long-time CTO, Vadim Tkachenko, has chosen to step away from the executive position to assume a new set of duties as Technology Fellow at Percona. As Technology Fellow, Tkachenko will focus on Percona’s involvement in the Linux Foundation’s Valkey Community, the growth of vector databases and other emerging technologies.
About Percona:
Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available.
Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424498483/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom